Boadie W Dunlop

Feb 5, 2025 | nature.com | Boadie W Dunlop |Charles Nemeroff |Helen S. Mayberg |W. Edward Craighead |Victoria Aranda

Treatments for major depressive disorder (MDD) include antidepressant medications and evidence-based psychotherapies, which are approximately equally efficacious. Individual response to treatment, however, is variable, implying individual differences that could allow for prospective differential prediction of treatment response and personalized treatment recommendation. We used machine learning to develop predictor variables that combined demographic and clinical items from a randomized clinical trial. The variables predicted a meaningful proportion of variance in end-of-treatment depression severity for cognitive behavioral therapy (39.7%), escitalopram (32.1%), and duloxetine (67.7%), leading to a high accuracy in predicting remission (71%). Further, we used these variables to simulate treatment recommendation and found that patients who received their recommended treatment had significantly improved depression severity and remission likelihood. Finally, the prediction algorithms and treatment recommendation tool were externally validated in an independent sample. These results represent a highly promising, easily implemented, potential advance for personalized medicine in MDD treatment.

Jul 25, 2024 | nature.com | Mathilde Antoniades |Stephen R. Arnott |Ki Sueng Choi |Benicio N. Frey |Melanie Ganz |Beata Godlewska | +18 more

Correction to: Nature Mental Health https://doi.org/10.1038/s44220-023-00187-w, published online 12 January 2024. In the version of the article initially published, the first affiliation of Melanie Ganz was incorrect and has now been amended to Neurobiology Research Unit, University Hospital Rigshospitalet, Copenhagen, Denmark in the HTML and PDF versions of the article.

Jun 27, 2024 | nature.com | Boadie W Dunlop |Helen S. Mayberg

Circuitry-based neuroimaging analyses can enhance our understanding of abnormal brain functioning in patients with major depressive disorder and other psychiatric conditions — but their utility for guiding treatment selection is less certain.

Jun 6, 2024 | nature.com | Rick Jansen |Yuri Milaneschi |Boadie W Dunlop |A. John Rush

AbstractMajor Depressive Disorder (MDD) is a common, frequently chronic condition characterized by substantial molecular alterations and pathway dysregulations. Single metabolite and targeted metabolomics platforms have revealed several metabolic alterations in depression, including energy metabolism, neurotransmission, and lipid metabolism. More comprehensive coverage of the metabolome is needed to further specify metabolic dysregulations in depression and reveal previously untargeted mechanisms.

Jul 26, 2023 | nature.com | Pirro G. Hysi |Annemarie I. Luik |Karl-Heinz Ladwig |Cristina Menni |M. Arfan Ikram |Karsten Suhre | +8 more

AbstractMetabolome reflects the interplay of genome and exposome at molecular level and thus can provide deep insights into the pathogenesis of a complex disease like major depression.